Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Andrew X Zhu et al.   LANCET ONCOLOGY

Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma

(2019) Linh Nguyen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)

(2019) A-L Cheng et al.   ANNALS OF ONCOLOGY

Cabozantinib exposure–response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma

(2019) Linh Nguyen et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2018) Peter R. Galle et al.   JOURNAL OF HEPATOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

(2018) Lorenza Rimassa et al.   LANCET ONCOLOGY

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

(2017) Masao Omata et al.   Hepatology International

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

(2016) Lorenza Rimassa et al.   Oncotarget

Hepatocellular carcinoma

(2016) Josep M. Llovet et al.   Nature Reviews Disease Primers

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

(2015) L Zhou et al.   ONCOGENE

Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

(2014) Q. Xiang et al.   CLINICAL CANCER RESEARCH

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE